Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1081-1090

  Morais, Lívia H ^a   Lima, Marcelo M S ^a   Martynhak, Bruno J ^a   Santiago, Ronise ^a   Takahashi, Tatiane T ^a   Ariza, Deborah ^a   Barbiero, Janaína K ^a   Andreatini, Roberto ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Depression; Dopamine; Parkinson's disease; Serotonin; Substantia nigra pars compacta; Turnover

Indexed keywords

DOPAMINE; NORADRENALIN; ROTENONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; FLUID INTAKE; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MORTALITY; NEUROTOXICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; OPEN FIELD TEST; PARKINSON DISEASE; PROTEIN METABOLISM; RAT;

EID: 84873739947     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70905-2     Document Type: Article

References (56)

1. Abbott RD, Ross GW, White LR, Sanderson WT, Burchfiel CM, Kashon M, Sharp DS et al.: Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study. J Neurol, 2003, 250, Suppl 3, 30-39. (Pubitemid 37297084)
2. Barbiero JK, Santiago RM, Lima MM, Ariza D, Morais LH, Andreatini R, Vital MA: Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res, 2010, 216, 186-192.
3. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E et al.: Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol, 2009, 219, 574-582.
4. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 2000, 3, 1301-1306.
5. Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S et al.: Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis, 2006, 22, 404-420. (Pubitemid 44294281)
6. Bjorklund A, Rosenblad C, Winkler C, Kirik D: Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis, 1997, 4, 186-200. (Pubitemid 27465509)
7. Borek LL, Amick MM, Friedman JH: Non-motor aspects of Parkinson's disease. CNS Spectr, 2006, 11, 541-554. (Pubitemid 44141222)
8. Ceravolo R, Sgado P, Frosini D, Corsini GU: Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo. J Neural Transm Suppl, 2006, 133-141. (Pubitemid 351412115)
9. Chapman LJ, Peters HA, Matthews CG, Levine RL: Parkinsonism and industrial chemicals. Lancet, 1987, 1, 332-333. (Pubitemid 17009823)
10. Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol, 2006, 5, 235-245. (Pubitemid 43238347)
11. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS: Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res, 2001, 124, 9-18. (Pubitemid 32567554)
12. Detke MJ, Rickels M, Lucki I: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl), 1995, 121, 66-72.
13. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S: Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine, 2008, 13, 37-48.
14. Ellenbroek B, Cools AR: The paw test: an animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci, 1988, 42, 1205-1213. (Pubitemid 18064273)
15. Ellenbroek B, Schwarz M, Sontag KH, Jaspers R, Cools A: Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res, 1985, 345, 132-140. (Pubitemid 16217923)
16. Ellenbroek BA, Prinssen EP, Cools AR: The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci, 1994, 6, 1-8. (Pubitemid 24022660)
17. Ellenbroek BA, Peeters BW, Honig WM, Cools AR: The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl), 1987, 93, 343-348. (Pubitemid 17160658)
18. Ferrante RJ, Schulz JB, Kowall NW, Beal MF: Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res, 1997, 753, 157-162. (Pubitemid 27156146)
19. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C: Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods, 2005, 148, 78-87. (Pubitemid 41423461)
20. Frisina PG, Haroutunian V, Libow LS: The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord, 2009, 15, 144-148.
21. Gorton LM, Vuckovic MG, Vertelkina N, Petzinger GM, Jakowec MW, Wood RI: Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res, 2011, 213, 253-262.
22. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG: Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci, 2011, 31, 141-142; author reply 142-143.
23. Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL et al.: Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol, 2008, 8, 6.
24. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC: Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine toxicity. Neurosci Lett, 1985, 62, 389-394. (Pubitemid 16147750)
25. Jeon BS, Jackson-Lewis V, Burke RE: 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration, 1995, 4, 131-137.
26. Kuter K, Kolasiewicz W, Gołembiowska K, Dziubina A, Schulze G, Berghauzen K, Wardas J, Ossowska K: Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats. Pharmacol Rep, 2011, 63, 1383-1392.
27. Lang AE, Lozano AM: Parkinson's disease. First of two parts. N Engl J Med, 1998, 339, 1044-1053. (Pubitemid 28457867)
28. Lang AE, Lozano AM: Parkinson's disease. Second of two parts. N Engl J Med, 1998, 339, 1130-1143. (Pubitemid 28465762)
29. Langston JW, Ballard PA, Jr.: Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med, 1983, 309, 310. (Pubitemid 13074924)
30. Langston JW, Ballard PA, Tetrud JW, Irwin I: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219, 979-980. (Pubitemid 13189531)
31. Lima MMS, Andersen ML, Reksidler AB, Vital MABF, Tufik S: The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE, 2007, 2, e513.
32. Lima MMS, Braga Reksidler A, Marques Zanata S, Bueno Machado H, Tufik S, Vital MA: Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res, 2006, 1101, 117-125. (Pubitemid 44036768)
33. Lima MMS, Reksidler AB, Vital MA: The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation. J Neural Transm Suppl, 2009, 73, 135-145.
34. Litteljohn D, Mangano E, Shukla N, Hayley S: Interferon-α deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience, 2009, 164, 1894-1906.
35. Lucki I: The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol, 1997, 8, 523-532.
36. Mayeux R: Depression in the patient with Parkinson's disease. J Clin Psychiatry, 1990, 51 Suppl, 20-23; discussion 24-25.
37. Mayeux R, Williams JB, Stern Y, Cote L: Depression and Parkinson's disease. Adv Neurol, 1984, 40, 241-250.
38. Mulcahy P, Walsh S, Paucard A, Rea K, Dowd E: Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience, 2011, 181, 234-242.
39. Papp M, Willner P, Muscat R: An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl), 1991, 104, 255-259.
40. Pereira M, Siba IP, Chioca LR, Correia D, Vital MA, Pizzolatti MG, Santos AR, Andreatini R: Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models. Prog Neuropsychopharmacol Biol Psychiatry, 35, 1636-1644.
41. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379-391.
42. Puschmann A, Pfeiffer RF, Stoessl AJ, Kuriakose R, Lash JL, Searcy JA, Strongosky AJ et al.: A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology, 2011, 76, 1623-1630.
43. Rajput AH, Uitti RJ, Stern W, Laverty W, O'Donnell K, O'Donnell D, Yuen WK, Dua A: Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci, 1987, 14, 414-418. (Pubitemid 17147624)
44. Reksidler AB, Lima MMS, Dombrowski P, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MABF: Repeated intranigral MPTP administration: A new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods, 2008, 167, 268-277. (Pubitemid 350235638)
45. Reksidler AB, Lima MMS, Zanata SM, Machado HB, da Cunha C, Andreatini R, Tufik S, Vital MABF: The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol, 2007, 560, 163-175. (Pubitemid 46341312)
46. Reneric JP, Bouvard M, Stinus L: In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res, 2002, 136, 521-532. (Pubitemid 35333268)
47. Santiago RM, Barbieiro J, Lima MM, Dombrowski PA, Andreatini R, Vital MA: Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry, 2010, 34, 1104-1114.
48. Saravanan KS, Sindhu KM, Mohanakumar KP: Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res, 2005, 1049, 147-155. (Pubitemid 41072930)
49. Segura Aguilar J, Kostrzewa RM: Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox Res, 2004, 6, 615-630.
50. Sherer TB, Kim JH, Betarbet R, Greenamyre JT: Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol, 2003, 179, 9-16. (Pubitemid 36062614)
51. Slattery DA, Markou A, Cryan JF: Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl), 2007, 190, 555-568. (Pubitemid 46204472)
52. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN: Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience, 2008, 156, 830-840.
53. Wang SH, Zhang ZJ, Guo YJ, Zhou H, Teng GJ, Chen BA: Anhedonia and activity deficits in rats: impact of post-stroke depression. J Psychopharmacol, 2009, 23, 295-304.
54. Weiss B: Vulnerability to pesticide neurotoxicity is a lifetime issue. Neurotoxicology, 2000, 21, 67-73.
55. Weisskopf MG, Knekt P, O'Reilly EJ, Lyytinen J, Reunanen A, Laden F, Altshul L, Ascherio A: Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology, 2011, 74, 1055-1061.
56. Xiong N, Huang J, Zhang Z, Zhang Z, Xiong J, Liu X, Jia M et al.: Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One, 2009, 4, e7878.